image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 0.345
-20 %
$ 18.1 M
Market Cap
-2.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ENZ stock under the worst case scenario is HIDDEN Compared to the current market price of 0.345 USD, Enzo Biochem, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ENZ stock under the base case scenario is HIDDEN Compared to the current market price of 0.345 USD, Enzo Biochem, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ENZ stock under the best case scenario is HIDDEN Compared to the current market price of 0.345 USD, Enzo Biochem, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ENZ

image
$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.315 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
31.9 M REVENUE
2.72%
-9.82 M OPERATING INCOME
60.31%
-26.1 M NET INCOME
-128.54%
-26.3 M OPERATING CASH FLOW
28.98%
-545 K INVESTING CASH FLOW
-0.55%
-4.19 M FINANCING CASH FLOW
-272.71%
7.33 M REVENUE
18.04%
-1.6 M OPERATING INCOME
47.83%
-1.54 M NET INCOME
54.53%
-2.03 M OPERATING CASH FLOW
77.46%
-70 K INVESTING CASH FLOW
-1.54%
-5.32 M FINANCING CASH FLOW
-2562.00%
Balance Sheet Enzo Biochem, Inc.
image
Current Assets 70 M
Cash & Short-Term Investments 52.4 M
Receivables 3.99 M
Other Current Assets 13.7 M
Non-Current Assets 15.7 M
Long-Term Investments 0
PP&E 15.2 M
Other Non-Current Assets 530 K
61.06 %4.65 %15.94 %17.73 %Total Assets$85.8m
Current Liabilities 24.8 M
Accounts Payable 1.38 M
Short-Term Debt 917 K
Other Current Liabilities 22.5 M
Non-Current Liabilities 4.86 M
Long-Term Debt 2.59 M
Other Non-Current Liabilities 2.27 M
4.64 %3.09 %75.88 %8.74 %7.64 %Total Liabilities$29.7m
EFFICIENCY
Earnings Waterfall Enzo Biochem, Inc.
image
Revenue 31.9 M
Cost Of Revenue 17.3 M
Gross Profit 14.6 M
Operating Expenses 27 M
Operating Income -9.82 M
Other Expenses 16.3 M
Net Income -26.1 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)32m(17m)15m(27m)(10m)(16m)(26m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
45.86% GROSS MARGIN
45.86%
-30.77% OPERATING MARGIN
-30.77%
-81.73% NET MARGIN
-81.73%
-46.47% ROE
-46.47%
-30.41% ROA
-30.41%
-15.86% ROIC
-15.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enzo Biochem, Inc.
image
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -26.1 M
Depreciation & Amortization 1.27 M
Capital Expenditures -545 K
Stock-Based Compensation 2.3 M
Change in Working Capital -8.25 M
Others 421 K
Free Cash Flow -26.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Enzo Biochem, Inc.
image
ENZ has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
16.80% DIVIDEND YIELD
0.1 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.10.10.10.10.10.10.10.10.00.00.00.00.00.00.10.1020242024
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Enzo Biochem, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. globenewswire.com - 2 weeks ago
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) the average closing price of the Company's Common Stock (the “Common Stock”) was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock. globenewswire.com - 2 months ago
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market. zacks.com - 3 months ago
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. globenewswire.com - 3 months ago
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions. zacks.com - 5 months ago
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. globenewswire.com - 5 months ago
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay. reuters.com - 7 months ago
Enzo Biochem: Is This Time Finally Different? Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks. seekingalpha.com - 8 months ago
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges. zacks.com - 9 months ago
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions. zacks.com - 9 months ago
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. globenewswire.com - 9 months ago
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. globenewswire.com - 1 year ago
8. Profile Summary

Enzo Biochem, Inc. ENZ

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 18.1 M
Dividend Yield 16.80%
Description Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Contact 527 Madison Avenue, New York, NY, 10022 https://www.enzo.com
IPO Date June 12, 1980
Employees 125
Officers Ms. Kara Cannon Chief Executive Officer & Director Ms. Patricia Eckert CPA Chief Financial Officer